

26th October 2023

- | | |
|---|--|
| <p>(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> <p>Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Dear Sir/Madam,

Sub: USFDA inspection at InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility unit 1 and 2 of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the Company) located in Hauppauge, Long Island, New York, USA from 16th October 2023 to 25th October 2023.

The inspection concluded with zero Form 483 observations.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Muskan Jain